LGALS3BP and neuroblastoma: Notably, significantly elevated expression of LGALS3BP in the serum or tumor tissue has been found to be associated with poor clinical outcome in patients with a variety of malignancies, including neuroblastoma [8,9,11,12,13,14,15,16].